Abstract
We report here the safety, efficacy, and platelet aggregability in 47 ischemic stroke patients who changed antiplatelet agents from ticlopidine to clopidogrel. The average age was 68 years old and 36 patients were atherothrombotic and 11 had lacuna infarction. After changing to clopidogrel, 3 patients had eruption and one had liver dysfunction; however, these side effects were not severe. After changing agents, none of the patients suffer stroke, but one patient suffered unstable angina and underwent intervention with coronary stent. Platelet aggregability was measured in 35 patients before and after changing antiplatelet agents. Seventeen patients (48.6％) showed the same platelet aggregability and 9 (25.7％) showed more depressed platelet aggregability after changing. Only two patients showed increased platelet aggregability. Changing from ticlopidine to clopidogrel was safe and effective in terms of clinical condition and platelet aggregability.
